Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2016. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), or Connected Persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than financial performance.
- Transaction Price: $39.01 per American Depositary Share (ADS).
- Transaction Date: January 7, 2016.
- Transaction Type: Increase in notional allocation of GSK ADSs within the GSK 401(K) plan due to cash element revaluation.
Material Changes
The filing details specific increases in notional ADS allocations for the following individuals:
- Dr M M Slaoui (Director/PDMR): 26 ADSs.
- Dr K Slaoui (Connected Person): 9 ADSs.
No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity and contains no forward-looking statements or risk assessments.
Investor Verification Checklist
- Verify the total number of ADSs held by Dr M M Slaoui and Dr K Slaoui following this transaction.
- Confirm the impact of the 401(K) plan revaluation on the notional investment value.
- Review the price of $39.01 per ADS against the market price on January 7, 2016.